Ligand-Binding Bioanalysis (Large Molecule) CROs
31 published
31 published CROs match Ligand-Binding Bioanalysis (Large Molecule).
Locations in this set include United States, China, United Kingdom, Australia, France, and India.
Capabilities that show up most often in this set: Small Molecule, Biologics (Monoclonal Antibodies), Biologics (Other), Cell Therapy, and Gene Therapy.
Matching companies
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Proone LabsProone Labs provides preclinical pharmacology, drug discovery, and regulatory support services to biotech startups, traditional pharma, and in-silico companies. The team has delivered 30+ assays, 50+ cell lines, and supported 4 FDA drug approvals across multiple therapeutic areas.
ProtheragenSpecialized preclinical CRO dedicated to obesity research, offering comprehensive animal models, pharmacokinetic/pharmacodynamic studies, bioanalysis, and safety assessment for anti-obesity drug development.
SannovaSannova provides bioanalytical and analytical CRO services, including immunogenicity and ligand binding assays, PK testing, DMPK services, extractables and leachables, nitrosamine testing, and pharmaceutical stability testing. Its listed work spans small molecules, biologics and biosimilars, and cell and gene therapies.
Simbec-OrionFull-service CRO delivering clinical trial management across early to late phases, with specialist expertise in rare diseases and oncology.
SoCal Biosciences, Inc.San Diego-based bioanalytical CRO specializing in assay development and analysis for mRNA, oligonucleotides, and large molecules across discovery through clinical development phases.- Swiss BioQuant AGBioanalytical CRO offering LC-MS/MS and ligand-binding assay development, validation, and sample analysis for small and large molecules. Work runs in a 21 CFR Part 11 compliant environment, with qPCR support for gene therapy bioanalysis.
Sword BioBioanalytical CRO offering ligand binding assay development, PK, immunogenicity (ADA and NAb), and custom biomarker assays under non-GLP, spirit-of-GLP, and GLP conditions. Supports clients from discovery through clinical Phase IV.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TigermedLeading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /services/ligand-binding-bioanalysis.md